Core Insights - Barinthus Biotherapeutics plc is advancing its clinical trials and has reported financial results for Q3 2024, highlighting significant progress in its pipeline, particularly in chronic hepatitis B and celiac disease treatments [1][2]. Clinical Developments - The company completed enrollment in the HBV003 trial of VTP-300 for chronic hepatitis B with 121 adult participants, aiming for a potential functional cure [3]. - Interim data from the HBV003 trial showed that 76% of participants met criteria for nucleos(t)ide analogue therapy discontinuation, with 19% achieving undetectable HBsAg levels [4]. - The first-in-human Phase 1 AVALON trial of VTP-1000 for celiac disease was initiated, focusing on safety and pharmacokinetics [5]. - Enrollment for the PCA001 trial of VTP-850 in prostate cancer was completed with 22 participants, with data expected in the first half of 2025 [6]. Financial Performance - As of September 30, 2024, the company reported cash and equivalents of 117.8 million at the end of Q2 2024, with a net cash usage of 15.0 million, attributed to royalties from Oxford University Innovation, compared to no revenue in Q2 2024 [9]. - Research and development expenses decreased to 11.7 million in Q2 2024, primarily due to reduced personnel costs [9][10]. - General and administrative expenses rose to 7.7 million [12]. - The net loss for Q3 2024 was (0.21) per share, an improvement from a net loss of $16.9 million in Q2 2024 [12][19]. Upcoming Milestones - Updated data from the VTP-300 program is expected in Q4 2024, with presentations at the AASLD – The Liver Meeting® 2024 [7]. - Data from the Phase 1 AVALON trial of VTP-1000 is anticipated in the first half of 2025 [8]. - Results from the Phase 1 PCA001 trial of VTP-850 are also expected in the first half of 2025 [8].
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results